Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 22% Improvement Relative Risk c19hcq.org Bubenek-Turconi et al. HCQ for COVID-19 ICU Is very late treatment with HCQ beneficial for COVID-19? Prospective study in Romania (March 2020 - March 2021) Lower mortality with HCQ (p=0.014) Bubenek-Turconi et al., European J. Anaesthesiol.., doi:10.1097/EJA.0000000000001776 Favors HCQ Favors control
Clinical characteristics and factors associated with ICU mortality during the first year of the SARS-Cov-2 pandemic in Romania
Bubenek-Turconi et al., European Journal of Anaesthesiology, doi:10.1097/EJA.0000000000001776
Bubenek-Turconi et al., Clinical characteristics and factors associated with ICU mortality during the first year of the SARS-Cov-2.., European Journal of Anaesthesiology, doi:10.1097/EJA.0000000000001776
Nov 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Prospective study of 9,058 COVID-19 ICU patients in Romania, showing lower mortality with HCQ treatment.
risk of death, 22.0% lower, OR 0.78, p = 0.01, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Bubenek-Turconi et al., 17 Nov 2022, prospective, Romania, peer-reviewed, 16 authors, study period March 2020 - March 2021.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit